Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.21 USD | +1.87% | +14.00% | -14.00% |
05-09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
05-09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.00% | 2.48B | |
+27.07% | 49.18B | |
+0.73% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.54% | 26.09B | |
-22.42% | 18.71B | |
+7.98% | 13.26B | |
+32.05% | 12.32B | |
+0.16% | 11.99B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Wedbush Lowers Intellia Therapeutics' Price Target to $29 From $45, Maintains Neutral Rating